Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a Psychiatrically-III Population

Clinical EEG and Neuroscience

Volumn 27, Issue , 1996, Pages 5-28

  Braverman, Eric R ^a   Blum, Kenneth ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL ABUSE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN MAPPING; DRUG DEPENDENCE; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPSYCHIATRY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SUBSTANCE ABUSE;

ALCOHOLISM; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; COCAINE; COMORBIDITY; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PSYCHOTIC DISORDERS; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 0029969050     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/1550059496027S0402     Document Type: Article

References (153)

1. Braverman ER. Brain mapping: A short guide to interpretation, philosophy and future. J Orthomolecular Med 1990; 5: 4.
2. Daniels EK Shenton ME Holzman PS, et al. Patterns of thought disorder associated with right cortical damage, schizophrenia, and mania. Amer J Psychiatry 1988; 145 (8):944-9.
3. Stoudemire A. Nelson A. Houpt JL. Interictal schizophrenia-like psychoses in temporal lobe epilepsy (Review). Psychosomatics 1983; 24 (4):331-3, 337-9.
4. Braverman ER. Brain electrical activity mapping in treatment resistant schizophrenics. J Orthomole Med 1990; 5 (1):46-48.
5. Morstyn R Duffy FH McCarley RW. Altered P300 topography in schizophrenia. Arch Gen Psychiatry 1983; 40 (7):729-34.
6. Karson CN Coppola R Morihisa JM Weinberger DR. Computed electroencephalographic activity mapping in schizophrenia: The resting state reconsidered. Arch Gen Psychiatry 1987; 44 (6):514-7.
7. Neshige R Kuroda Y Kakigi R, et al. Event-related brain potentials as indicators of visual recognition and detection of criminals by their use. Forensic Sci Int 1991; 51 (1):95-103.
8. Blanchey MH Buydens-Blanchey L Horvath TB. Event-related potentials in substance abusers after long-term abstinence. Biol Psychiatry 1992; 31: 61A-252A.
9. Vasile RG Duffy FH McAnulty G, et al. Abnormal flash visual evoked response in melancholia: A replication study. Biol Psychiatry 1992; 31 (4):325-36.
10. Duffy FH Albert MS McAnulty G. Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type, Ann Neurol 1984; 16 (4):439-48.
11. deToledo-Morrell L Evers S Hoeppner TJ, et al. A 'stress' test for memory dysfunction: Electrophysiological manifestations of early Alzheimer's disease. Arch Neurol 1991; 48 (6):605-9.
12. Bernad PG. EEG and pesticides (Review). Clin Electroencephalogr 1989; 20 (2):IX-X.
13. Morrow LA Steinhauer SR Hodgson MJ. Delay in P300 latency in patients with organic solvent exposure. Arch Neurol 1992; 49 (3):315-20.
14. Knoll O, et al. EEG indicates aluminum load in long term hemodialysis patients. Trace Elements Med 1984; 1: 54-58.
15. Kugler CF Lotterer E Petter J, et al. Visual event-related P300 potentials in early portosystemic encephalopathy. Gastroenterology 1992; 103 (1):302-10.
16. Messenheimer JA Robertson KR Wilkins JW, et al. Event-related potentials in human immunodeficiency virus infection. Arch Neurol 1992; 49 (4):396-400.
17. Buschbaum M Wender P. Average evoked responses in normal and minimally brain dysfunctioned children treated with amphetamine. Arch Gen Psychiatry 1973; 29 (6):764-70.
18. Halliday R Rosenthal JH Naylor H Callaway E. Averaged evoked potential predictors of clinical improvement in hyperactive children treated with methylphenidate: An initial study and replication. Psychophysiology 1976; 13 (5):429-40.
19. Prichep LS Sutton S Hakerem G. Evoked potentials in hyperkinetic and normal children under certainty and uncertainty: A placebo and methylphenidate study. Psychophysiology 1976; 13 (5):419-28.
20. Cohen HL Porjesz B Begleiter H. EEG characteristics in males at risk for alcoholism. Alcohol Clin Exp Res 1991; 15 (5):858-61.
21. Pollock VE Gabrielli WF Mednick A. Goodwin DW. EEG identification of subgroups of mean at risk for alcoholism. Psychiatry Res 1988; 26 (1):101-4.
22. Ehlers CL Schuckit MA. EEG fast frequency activity in the sons of alcoholics. Biol Psychiatry 1990; 27 (6):631-41.
23. Pollock VE Volavka J Goodwin DW, et al. The EEG after alcohol administration in men at risk for alcoholism. Arch Gen Psychiatry 1983; 40 (8):857-61.
24. Struve FA Straumanis JJ. Electroencephalographic and evoked potentials methods in human marijuana research: Historical review and future trends. Drug Develop Res 1990; 20: 369-388.
25. Braverman ER Blum K Smayda RJ. A commentary on brain mapping in 60 substance abusers: Can the potential for drug abuse be predicted and prevented by treatment? Cur Ther Res 1990; 48 (4):569-585.
26. Struve F Straumanis JJ. Separation of chronic marijuana (THC) users from nonusers: A discriminant function analysis using quantitative electroencephalographic variables. Biol Psychiatry 1990; 27: 52A-53A.
27. Struve F Straumanis JJ. Persistent topographic quantitative EEG changes in chronic marihuana (THC) use: A replication study. Biol Psychiatry 1989; 25: 29A.
28. Abraham HD Duffy FH. Computed EEG abnormalities in panic disorder with and without premorbid drug abuse. Biol Psychiatry 1991; 29 (7):687-90.
29. Cadaviera F Grau C Roso M Sanchez-Turet M. Multimodality exploration of event-related potentials in chronic alcoholics. Alcohol Clin Exp Res 1991; 15 (4):607-11.
30. Begleiter H Porjesz B. Potential biological markers in individuals at high risk for developing alcoholism (Review). Alcohol Clin Exp Res 1988; 12 (4):488-93.
31. Begleiter H Porjesz B. Neurological processes in individuals at risk for alcoholism (Review). Alcohol 1990; 25 (2-3):251-6.
32. Maurer K Dierks T Strik WK Frolich L. P3 topography in psychiatry and psychopharmacology. Brain Topogr 1990; 3 (1):79-84.
33. Pfefferbaum A. Ford JM White PM Mathalon D. Event-related potentials in alcoholic men: P3 amplitude reflects family history but not alcohol consumption. Alcohol Clin Exp Res 1991; 15 (5):839-50.
34. Noldy NE Carlen PL Santos CV. Quantitative EEG and P300 in cocaine withdrawal. Brain Topography 1990; 3 (1):262-263.
35. Braverman ER Smith R Smayda R Blum K. Modification of P300 amplitude and other electrophysiological parameters of drug abuse by cranial electrical stimulation. Cur Ther Res 1990; 48: 586-596.
36. Whipple SC Parker ES Noble EP. An atypical neurocognitive profile in alcoholic fathers and their sons. J Stud Alcohol 1983; 49 (3):240-4.
37. Parsons OA Sinha R Williams HL. Relationships between neuropsychological test performance and event-related potentials in alcoholic and nonalcoholic samples. Alcohol Clin Exp Res 1990; 14 (5):746-55.
38. Garber HJ Weilburg JB Duffy FH Manschreck TC. Clinical use of topographic brain electrical activity mapping in psychiatry. J Clin Psych 1989; 50 (6):205-11.
39. American Psychiatric Association Task Force: Quantitative electroencephalography: A report on the present state of computerized EEG techniques. Am J Psychiatry 1991; 148 (7):961-4.
40. Duffy FH Hughes JR Miranda F Bernad P Cook P. Status of quantitative EEG (QEEG) in clinical practice, 1994. Clin Electroencephalogr 1994; 25 (4):VI.
41. Mehra IV. The electroencephalograms: Its patterns and origins. JAMA 1994; 272 (17):1325-1326.
42. Riley T. JAMA 1994; 271: 1456. Review of Barlow JS, (ed). The Electroencephalograms: its patterns and origins. Cambridge, Mass: MIT Press, 1993.
43. Post RM Trimble MR Pippenger CE. Use of anticonvulsants in the treatment of manic-depressive illness. Clin Use of Anticonvulsants in Psychiatric Disorders. Demos Publications 1989: 113-153.
44. Post RM Trimble MR Pippenger CE. Anticonvulsants as adjuncts to neuroleptics in the treatment of schizoaffective and schizophrenic patients. Clin Use of Anticonvulsants in Psychiatric Disorders. Demos Publications 1989: 153.
45. Post RM Trimble MR Pippenger CE. Anticonvulsants in the treatment of aggression and dyscontrol. Clin Use of Anticonvulsants in Psychiatric Disorders. Demos Publications 1989: 165.
46. Koob GF Voccurino FJ Amaric M. Neurochemical substrates for opiate reinforcement. In: Fisher S, Raskin A., Uhlenhuth EH, (eds). Aspects. New York: Oxford University Press, 1987: 80-108.
47. Blum K Kozlowski GP. Ethanol and neuromodulator interactions: A cascade model of reward. In: Oliat H, Parvez S, Parvez H, (eds). Progress In Alcohol Research. 1990b: 131-147.
48. Ballenger JC Post RM. Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 1980; 137 (7):782-90.
49. Goldstein RB Especially MM Adams PB, et al. Psychiatric disorders in relatives of probands with panic disorder and/or major depression. Arch Gen Psychiatry 1994; 51 (5) 383-94, Division of Clinical and Genetic Epidemiology, New York State Psychiatric Institute, NY.
50. Brown GW Hines JC Fisher P Ray DS. Isolation of the genes encoding the 51-kilodalton and 28-kilodalton subunits of crithidiafasciculata replication protein A. University of London. Mol Biochem Parasitol Jan 1994; 63 (1):135-42.
51. Abbott JP Weller SB Walker RS. Psychiatric disorders of opioid addicts entering treatment: Preliminary data. J Addictive Diseases 1994; 13 (3):1-12.
52. Gerez M Tello A. Clinical significance of focal topographic changes in the electroencephalogram (EEG) and evoked potentials (EP) of psychiatric patients. Brain Topogr 1992; 5 (1):3-10.
53. Halikas JA Kuhn KL Crea FS, et al. Treatment of crack cocaine use with carbamazepine. Am J Drug Alcohol Abuse 1992; 18 (1):45-56.
54. Chu NS. Carbamazepine: Prevention of alcohol withdrawal seizures. Neurology 1979; 29 (10):1397-1401.
55. Mott SH Packer RJ Soldin SJ. Neurologic manifestations of cocaine exposure in childhood. Pediatrics. 1994; 93 (4):557.
56. Stuppaeck CH Pycha R Miller C Whitworth A.B., et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: A double-blind study. Alcohol 1992; 27 (2): 153-8.
57. Campbell J.L, et al. Impact on desipramine or carbamazepine on patient retention in outpatient cocaine treatment: Preliminary findings. J Addictive Diseases 1994; 4 (13):191-199.
58. Latkin CA Mandell W. Depression as an antecedent of frequency of intravenous drug use in an urban, nontreatment sample. Inter J Addictions 1993; 28 (14):1601-12.
59. Maier W Minges J Lichtermann D. Alcoholism and panic disorder: Co-occurrence and co-transmission in families. Eur Arch Clin Neuroses 1993; 243: 205-11.
60. Dinwiddie SH Reich T Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry 1992; 53 (10):364-9.
61. Brown SA Inaba RK Gillin JC Schuckit MA Stewart MA Irwin MR. Alcoholisn and affective disorder: Clinical course of depressive symptoms. Am J Psych 1994; 152 (1):45.
62. Holmes TH Rahe RH. The social readjustment rating scale. J Psychosomatic Res 1967; 11 (2):213-18.
63. Fendrich M Mackesy-Amiti ME. Inconsistencies in lifetime cocaine and marijuana use reports: Impact on prevalence and incidence. Society for the Study of Addiction to Alcohol and Other Drugs 1995; 90: 111-118.
64. Miller NS. Issues in the diagnosis and treatment of comorbid addictive and other psychiatric disorders. Direction in Psychiatry. The Hatherleigh Co. Ltd. 1994; 14 (25).
65. Blum K Noble EP Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990; 263 (15):2055-60.
66. Blum K Noble EP Sheridan PJ, et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991; 8 (5):409-16.
67. Blum K Noble EP Sheridan PJ, et al. Genetic predisposition in alcoholism: Association of the D2 dopamine receptor Taql B1 RFLP with severe alcoholics. Alcohol 1993; 10 (1):59-67.
68. Treiman DM Walton NY Kendrick C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 1990; 5 (1);49-60.
69. Blom JL Anneveldt M. An electrode cap tested. Electroencephalogr Clin Neurophysiol 1982; 54 (5):591-4.
70. Blom JL Mechelse K. The EEG profile. In: Lechner H, Aranibar A., (eds). EEG and Clinical Neurophysiology, Excerpta Medica, Int Congr Ser 526. Amsterdam; 1980: 338-46.
71. Klass DD Sharborough FW. Electroencephalography. In: Aronson E, Auger RG, Bastron JS, et al, (eds). Clinical examination in neurology. Mayo Clinic and Mayo Foundation 5th ed. Philadelphia; WB Saunders, 1981; 278-99.
72. Duffy FH Albert MS McAnulty G Garvey AJ. Age-related differences in brain electrical activity of healthy subjects. Ann Neurol 1984; 16 (4):430-8.
73. Barajas JJ. The effects of age on human P3 latency. Acta Otolaryngol (Stockh) 1991. (suppl); 476: 157-160.
74. Maus A. Endresen J. Misuse of computer-generated results. Med Biol Eng Comput 1979; 17: 126-129.
75. Abt K. Problems of repeated significance testing. Controlled Clinical Trials 1981; 1: 377-381.
76. Abt K. Significance testing of many variables - problems and solutions. Neuropsychobiol 1983; 9: 47-51.
77. Oken BS. HCK Statistical issues concerning computerized analysis of brainwave topography. Ann Neurol 1986; 19: 493-494.
78. Duffy FH. Clinical decision making in quantified electroencephalographic analysis. In: Samson-Dollfus D, Gotman J, Guieu JD, Etevenon P, (eds). Statistics and Topography in Quantitative EEG. Paris: Elsevier, 1988: 9-26.
79. Coste J Fermanian J Venot A. Methodological and statistical problems in the construction of composite measurement scales: A survey of six medical and epidemiological journals. Statistics in Medicine 1995; 14: 331-345.
80. Bartels PH. Numerical evaluation of cytologic data VIII. Computation of the principal components. Annal Quant Cytol 1981; 3: 83-90.
81. Bartels PH. Numerical evaluation of cytologic data IX. Search for data structure by principal components transformation. Annal Quant Cytol 1981; 3: 167-177.
82. Duffy F Jones K Bartels P McAnulty G Albert M. Unrestricted principal components analysis of brain electrical activity; issues of data dimensionality, artifact, and utility. Brain Topogr 1992; 4: 291-307.
83. Mayberg HS. Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosciences 1994; 6: 428-442.
84. Braverman ER. Brain electrical activity mapping (BEAM) in patients who commit violent crimes: Are bitemporal abnormalities a characteristic? J Orthomolecular Med 1993; 8 (3):54-56.
85. Miller NS Hoffmann NG. Depression associated with alcohol/other drug addiction. J Addiction 1994; 13 (2).
86. Ziedonia DM Rayford BS Bryant KJ Rounsaville BJ. Psychiatric comorbidity in white and African-American cocaine addicts seeking substance abuse treatment. Hospital Community Psychiatry 1994; 45 (1).
87. Westermeyer J Specker S Neider J Lingenfelter MA. Substance abuse and associated psychiatric disorder among 100 adolescents. J Addictive Diseases 1994; 13 (1).
88. Wills TA Vaccaro D Schreibman D Benson G. Psychosocial predictors of early-onset substance use. Ann Behavioral Med 1994; 16.
89. McCormick LH. Mothers of children with attention deficit are at risk of depression. American Academy of Family Physicians 1995; 657.
90. Biederman J, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792-1798.
91. Blackwood DH Muir WJ. Cognitive brain potentials and their application (Review). Br J Psychiatry Suppl 1990; 157 (9):96-101.
92. Jacobson SA Leuchter AF Walter DO. Conventional and quantitative EEG in the diagnosis of delirium among the elderly. J Neurol Neurosurg Psychiatry 1993; 56 (2):153-8.
93. Blum K Braverman ER Wood RC Sheridan PJ, DRD2 Al allele and P300 abnormalities in obesity (abstract). Presented at the American Society of Human Genetics meeting, Montreal, Canada, October 28. Am J Hum Genet 1994.
94. Cornelius JR Salloum IM Mezzich J, et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry 1995; 152: 3.
95. Perryman KM Fitten LJ. Impact of attentional deficits on driving performance of the elderly and individuals with mild Alzheimer's disease. Facts Res Gerontology 1994; 409-420.
96. Wolfe N Reed BR Eberling JL Jagust WJ. Temporal lobe perfusion on single photon emission computed tomography predicts that rate of cognitive decline in Alzheimer's disease. Arch Neurol 1995; 52 (3).
97. Koshino Y Muata T Oomori M Horie T Isaki K Tsubokawa M Hamada T Fukui J. Temporal minor slow and sharp activity in psychiatric patients. Clin Electroencephalogr 1990; 21 (4):225-232.
98. Kowell A. A referring physician's view of neurological assessment. Fifth Annual International PET Conference. McClean, Virginia. October 28-31, 1993.
99. Porjesz B Begleiter H Bihari B Kissin B. N2 component of the event-related brain potential in abstinent alcoholics. Electroencephalogr Clin Neurophysiol 1987; 66 (2):121-31.
100. Rockstroh B Elbert T Lutzenberger W Altenmuller E. Effects of the anticonvulsants benzodiazepine clonazepam on event-related brain potentials in humans. Electroencephalogr Clin Neurophysiol 1991; 78 (2):142-9.
101. Kirby AW Wiley RW Harding TH. Cholinergic effects on the visual evoked potential. Evoked Potential 1986; 26: 296-306.
102. Fukuda M Hiramatsu K Honda M, et al. Shortening of N1 and P3 latencies in event-related potentials observed coincidentally with clinical improvement during nootropic medication in a demented patient: Specific effect of nicergoline. Jpn J Psychiatry Neurol 1992; 46 (4):919-25.
103. Maurer K Dierks T Laux G, et al. Topographic mapping of EEG and auditory evoked P300 in neuropsychopharmacology (topographic pharmaco-EEG and pharmaco-AEP 300). Pharmacopsychiatry 1988; 21 (6):338-42.
104. Maurer K Dierks T Strik WK Frolich L. P3 topography in psychiatry and psychopharmacology. Brain Topogr 1990; 3 (1):79-84.
105. Defrance JF Hymel C Trachtenberg MC, et al. Enkephalinase-inhibition and precursor amino acid loading enhances attention processing and P300 in healthy humans. Amer Psychiatric Electrophysiology Assoc, 2nd Annual Meeting, Philadelphia, PA, May 20, 1994.
106. Thatcher RW Fishbein DH. Computerized EEG, nutrition and behavior. J Applied Nutrition 1984; 36 (2):81-92.
107. Epstein CM Trotter JF Averbook A., et al. EEG mean frequencies are sensitive indices of phenylalanine effects on normal brain. Electroencephalogr Clin Neurophysiol 1989; 72 (2):133-9.
108. Araki SA Muata K Yokoyama K Uchida E. Auditory event-related potential (P300) in relation to peripheral nerve conduction in workers exposed to lead, zinc, and copper: Effects of lead on cognitive function and central nervous system. Am J Ind Med 1992; 21 (4):539-47.
109. Lester ML Horst RL Thatcher RW. Protective effects of zinc and calcium against heavy metal impairment of children's cognitive function. Nutrition Behavior 1986; 3: 145-61.
110. Christensen L Bourgeois A. Cockroft R. Dietary alteration of somatic symptoms and regional brain electrical activity. Biol Psychiatry 1991; 29 (7):679-82.
111. Peniston EG Kulkosky PJ. Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcohol Clin Exp Res 1989; 13 (2):271-9.
112. Pockberger H Rappelsberger P Petsche H, et al. Computer-assisted EEG topography as a tool in the evaluation of actions of psychoactive drugs in patients. Neuropsychobiology 1984; 12 (2-3):183-7.
113. Itil TM Eralp E Itil KZ, et al. CEEG dynamic brain mapping: a new method to evaluate brain function in different psychological and drug conditions. Symposium Electric and Magnetic Activity of the CNS; Research and Clinical Application in Aerospace Medicine. Advisory Group for Aerospace Research and Development, 1987.
114. Sloan EP Fenton GW Standage KP. Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory. Biol Psychiatry 1992; 31 (6):600-6.
115. Nobilio D, et al. Effect of levo-acetyl-carnitine on P300 potential. Curr Ther Res 1990; 47: 267-77.
116. McNamara ME. Advances in EEG-based diagnostic technologies. In: Stoudemire A., Fogel BS, (eds). Med Psych Practice. Vol. 1. Washington, DC: American Psychiatric Press, 1991: 163-89.
117. Pollock VE Schneider LS. Quantitative, walking EEG research on depression. Society Biological Psychiatry 1990; 27: 257-780.
118. Morihisa JM McAnulty GB. Structure and function: Brain electrical activity mapping and computed tomography in schizophrenia. Biol Psychiatry 1985; 20: 3-19.
119. Benson DF. The role of frontal dysfunction in attention deficit hyperactivity disorder. J Child Neurology 1991; 6: S9-S12.
120. Mann CA Lubar JF Zimmerman AW Miller CA Muenchen RA. Quantitative analysis of EEG in boys with attention-deficit-hyperactivity disorder: Controlled study with clinical implications. Pediatric Neurology. 8 (1):30-36.
121. Noble EP Syndulko K Fitch RJ, et al. D2 receptor TAQ I an alleles in alcoholic and nonalcoholic patients. Alcohol and Alcoholism 1994, in press.
122. Parsian A. Todd RD Devor EJ, et al. Alcoholism and alleles of the human D2 dopamine receptor locus: Studies of association and linkage. Arch Gen Psychiatry 1991; 48 (7):655-63.
123. Arinami T Itokawa M Komiyama T, et al. Association between severity of alcoholism and the A1 allele of the dopamine D2 receptor gene TAQ I A RFLP (in Japanese). Biol Psychiatry 1993; 33 (2):108-14.
124. Amadeo S Abban M Fourcade ML, et al. D2 dopamine receptor gene and alcoholism. J Psychiatr Res 1993; 27 (2):173-9.
125. Cook CC Holmes D Breh P, et al. Linkage analysis confirms a genetic effect at the D2 dopamine receptor locus in heavy drinking and alcoholism. Neuropsychogenetics (in press).
126. Smith SS O'Hara BF Persico AM, et al. Genetic vulnerability to drug abuse: The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry 1992; 49 (9):723-7.
127. Noble EP Blum K Khalsa ME, et al. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 1993; 33 (3):271-85.
128. Comings DE MacMurray J Johnson JP, et al. The dopamine D2 receptor gene: A genetic risk factor in polysubstance abuse. Drug Alcohol Dependence (in press).
129. Uhl G Blum K Noble E Smith S. Substance abuse vulnerability and D2 receptor genes. Trends Neurosci 1993; 16 (3):83-88.
130. Comings DE Comings BG Muhleman D, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266 (13):1793-800.
131. Noble EP Noble RE Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with obesity. Int J Eating Disorders 1994 (in press).
132. Noble EP Blum K Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48 (7):648-54.
133. McBride NJ Chernet E Dyr W, et al. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol 1993; 10 (5):387-90.
134. Berman SM Whipple SC Fitch RJ Noble EP. P3 in young boys as a predictor of adolescent substance use. Alcohol 1993; 10 (1):69-76.
135. Noble EP, et al. Prolonged P300 latency in children with the D2 dopamine receptor A1 allele. Am J Hum Genet, 54: 658-668.
136. Lawford B.R. Young RM Qualichefski J. Rowell, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nature Medicine 1995.
137. Blum K Braverman ER Dinardo MJ Wood RC Sheridan PJ. Prolonged P300 latency in a neuropsychiatric population with the D2 Dopamine receptor A1 allele. Pharmacogenetics 1994; 4: 313-322.
138. Christian JC Edenburg H O'Connor SJ, et al. Association s of dopamine D2 polymorphisms with brain electrophysiology. Alcoholism 1994; 18 (2): 178 (abstract).
139. Blum K Sheridan PJ Wood RC, et al. Dopamine D2 receptor gene variants: Association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995; 5: 121-141.
140. Lovinger DM Grant KA. Alcohol neurotoxicity: Effects and mechanisms. Handbook of Neurotoxicology.
141. Seiden LS Sabol KE. Neurotoxicity of methamphetamine-related drugs and cocaine. Handbook of Neurotoxicology.
142. Teens' drug use rises as perceived risk drops. The Wall Street Journal, Jan 1995.
143. Hudson J. Drug abuse increases among U.S. teenagers as beliefs about drugs' dangers soften. Psychiatric Times, Feb 1995; 35-36.
144. Gordon HW. Human neuroscience at National Institute on Drug Abuse: Implications for genetics research. Am J Med Gen 1994; 54: 300-303.
145. Neiswanger K Hill S.Y. Kaplan BB. Association between alcoholism and the TAQ I A RFLP of the dopamine D2 receptor gene in the absence of linkage. Psychiatric Genetics, 1993; 3: 130 (abstract).
146. Neiswanger K Hill S.S.Y. Kaplan BB. Association between alcoholism and the TAQ I A RFLP of the dopamine D2 receptor gene in the absence of linkage. Neuropsychiatric Genetics, Am J Med Gen, 1995 (in press).
147. Kokkevi A. Stefanis C. Drug abuse and psychiatric comorbidity. Com Psych, 1995; 36 (5):329-337.
148. Nunes EV McGrath PJ Quitkin FM. Treating anxiety in patients with alcoholism. J Clin Psychiatry 1995; 56 (2).
149. Monahan J. Violence among mentally ill found to be concentrated among those with comorbid substance abuse disorders. Psychiatric News. Dec, 1995.
150. Adams KM Gilman S Koeppe RA. Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. Alcoholism: Clin Exp Res. 1993; 17 (2).
151. Gilman S Adams K Koeppe RA, et al. Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studies with positron emission tomography. Annals Neurology 1990; 28 (6).
152. Adams KM Gilman S Koeppe R, et al. Correlation of neuropsychological function with cerebral metabolic rate in subdivisions of the frontal lobes of older alcoholic patients measured with {18F} fluorodeoxyglucose and positron emision tomography. Neuropsychology 1995; 9 (3):275-280.
153. Blum K Cull JC Braverman ER Comings DE. Reward Deficiency Syndrome. American Scientist, 1996; 84: 132-145.